“IBI303 is highly similar to adalimumab in spatial structure; pharmacodynamic and toxicokinetic studies have shown similar results for both drugs,” they added. “The in vitro inhibitory ...

We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis. This multinational phase 3 trial involved adults ...

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time ...

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of adalimumab in the ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the ...

Back to Healio Upadacitinib continues to maintain higher levels of clinical response, compared with adalimumab, in patients with rheumatoid arthritis through 3 years, according to data presented ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adalimumab (Humira) in addition to surgery for moderate to severe hidradenitis suppurativa (HS) significantly increased ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa ...